ClinicalTrials.gg
CompletedNCT05628259Updated Mar 13, 2024

The Effect of Tele-Nursing Based Motivational Interviewing in Individuals With Type 2 Diabetes:RCT

An interventional study of Tele-Nursing based Motivational Interviewing in Type2 Diabetes, Self Efficacy and Self Management, sponsored by Pamukkale University. Completed at 3 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Pamukkale University · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies in Hyperlipoproteinemia Type II with a site in Turkey — 5 open to participants now, 5 under way, 5 of them phase 3. Hyperlipoproteinemia Type II · Turkey.

Enrollment
10th of 12
70 · median 179
Started
2023
with 2 others
No phase
Only one
of the 13
Registered
8th of 13
by date
Lead sponsor
1 of 13
Pamukkale University

Among the 13 studies in Hyperlipoproteinemia Type II with a site in Turkey, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is the only one with no phase, and was the 8th registered.

Hyperlipoproteinemia Type II

251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

5 of the 13 studies in Hyperlipoproteinemia Type II with a site in Turkey are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hyperlipoproteinemia Type II with a site in Turkey, or all of them as a file.
02

Study summary

This study carried out to examine the effect of tele-nursing based motivational interviewing on diabetes self-efficacy, diabetes self-management and metabolic control parameters (Body mass index, waist circumference, HbA1c%,fasting blood glucose, LDL cholesterol, HDL cholesterol, total cholesterol, triglyceride) in individuals with type 2 diabetes.

Read the detailed description

The first researcher of the article who applied Motivational Interviewing Techniques has a "Motivational Interviewing Techniques Training" certificate. A motivational interview (MI) program based on the telenursing approach was prepared by the researchers based on the literature for the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.

03

Conditions studied

  • Type2 Diabetes
  • Self Efficacy
  • Self Management
  • Tele-nursing
  • Motivational Interview
  • LDL - Low Density Lipoprotein Receptor Disorder
  • High Density Lipoprotein Deficiency
  • Cholesterol; Lipidosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. being over 18 years old, 2) receiving insulin or insulin + oral therapy, 3) diagnosis of type 2 diabetes at least one year ago, 4) having a of 25 and above, 5) value of 7 and above, 6) access to phone, 7) voluntarily agreeing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. have a physical disability.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Intervention Group

    A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.

    Behavioral: Tele-Nursing based Motivational Interviewing

  • No intervention
    Control Group

    The control group received routine nursing care in the diabetes policlinic.

Interventions

  • BehavioralTele-Nursing based Motivational Interviewing

    A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.

06

What researchers measure

Primary outcomes

  1. Diabetes Self-Efficacy Scale

    The change in diabetes self efficacy of individuals with Type 2 diabetes at 3rd month and 6 rd month with the Diabetes Self-Efficacy Scale.

    Time frame: Change from Baseline diabetes self-efficacy at 6 months

  2. Diabetes Self-Management Scale

    This scale was used to measure the behavioral component of individuals in the IMB model. The validity and reliability study of the Turkish Diabetes Self-Management Perception Scale was conducted by Eroğlu and Sabuncu (2018). The scale consists of 16 items and 4 sub-dimensions and is a 4-point Likert type. Glucose Management sub-dimension: Items 4, 6, 10, 12 (items 4 and 12 are about drug use, items 1, 6 and 10 are about blood glucose monitoring). Diet Control sub-dimension: Items 2, 5, 9, 13. Physical Activity sub-dimension: Items 8, 11, 15. Use of Health Services sub-dimension: It consists of 3, 7, 14, and 16 items. The DMS scale consists of 16 items, 7 of which are straight and 9 of which are reversed. The scores of the items numbered "5, 7, 10, 11, 12, 13, 14, 15 and 16" in the scale are calculated by reversing them. Diabetes self-management increases as the score gets closer to 10.

    Time frame: Change from Baseline diabetes self-management at 6 months

Secondary outcomes

  1. HbA1c%

    Hemoglobin A1C

    Time frame: Change from Baseline HbA1c% at 6 months

  2. BMI

    Body Mass Index

    Time frame: Change from Baseline Body Mass Index at 6 months

  3. FBG

    Fasting blood glucose

    Time frame: Change from Baseline Fasting glucose at 6 months

  4. LDL

    Low-density lipoprotein

    Time frame: Change from Baseline LDL at 6 months

  5. HDL

    High-density lipoprotein

    Time frame: Change from Baseline HDL at 6 months

  6. waist circumference

    waist circumference

    Time frame: Change from Baseline waist circumference at 6 months

  7. Total cholesterol

    Total cholesterol

    Time frame: Change from Baseline total cholesterol at 6 months

  8. Triglyceride

    triglyceride

    Time frame: Change from Baseline total triglyceride at 6 months

07

Study locations

3 sites
  • Eda Kılınç İşleyen
    Pamukkale, Denizli (545)-561 96 83, Turkey
  • İrem Nur ÖZDEMİR
    Istanbul, Turkey
  • Şengül AYDIN YOLDEMİR
    Istanbul, Turkey
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in May 2023, 3 months.

Of 37 non-industry interventional studies with no phase under Hyperlipoproteinemia Type II, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 3 months is below that.

Counting every sponsor, half of 39 studies reached it within 29 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2022
First posted
Nov 28, 2022
StartActual
Feb 1, 2023
Primary completionActual
May 2, 2023
CompletionActual
Oct 2, 2023
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05628259
Responsible party
EDA KILINÇ İŞLEYEN (Assistant Profesor Dr., Pamukkale University) — Principal investigator
First posted
Nov 28, 2022
Start date
Feb 1, 2023
Primary completion
May 2, 2023
Completion
Oct 2, 2023
Last update
Mar 13, 2024

Study contacts

Eda KILINÇ İŞLEYEN, PhD. RN.
study chair · Uşak University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion